| Abstrakt: |
Background: Breast carcinoma is the most prevalent carcinoma in female worldwide, about 2.3 million new breast carcinoma cases and 685,000 breast carcinoma deaths worldwide in 2020. These tumors are heterogeneous in terms of histology (mainly ductal, lobular, mixed ductal and lobular, cribriform, mucinous, medullary, and tubular carcinomas), natural history, and response to treatment. Objective: To find retrospectively prognostic parameter difference between breast carcinoma subtypes Luminal A, Luminal B. and 5-year rates of (OS), (DFS) in female diagnosed with luminal early-stage breast carcinoma at clinical oncology department, faculty of Medicine, Beni-Suef University Hospital from Jan 2015 till December 2019. Patients and Methods: the current study is retrospective cross-sectional, conducted in Clinical Oncology Department in Beni-Suef University from Jan 2015 till Dec 2019. Results: There was significantly difference between luminal A, luminal B regarding age, as most patients more than 60 yrs old had luminal A breast cancer. There no significantly differences between luminal A, luminal B regarding DFS,OS but time of DFS, OS in luminal A was longer,as luminal A is the best prognosis of molecular subtypes. There was significantly differences between luminal A, luminal B regarding chemotherapy, which most of luminal A not received chemotherapy, because luminal A breast cancer less benefit of chemotherapy. There was significant association between T3 and younger age less than 40 years but from 40 to 60 and above 60 there was no significant association with T1, 2&3. There was a significant association between ages more than 60 years and lower Ki67.There was significant higher overall survival in patients without comorbitities than patients with DM or HTN or both. Conclusion: The current study, Luminal B almost depend on high ki67 which is not riable test, so no significantly difference between Luminal A, Luminal B regarding OS, DFS. But time of DFS, OS is longer in Luminal A than Luminal B, this confirm Luminal A is the best prognosis of molecular subtypes of breast carcinoma. [ABSTRACT FROM AUTHOR] |
